Peranan Inotropik dan Vasopresor dalam Terapi Syok Kardiogenik
DOI:
https://doi.org/10.55175/cdk.v48i6.78Kata Kunci:
vasopresor, syok kardiogenik, InotropikAbstrak
Syok kardiogenik merupakan keadaan darurat medis yang mengancam jiwa dengan terjadinya hipoperfusi jaringan akibat berkurangnya curah jantung. Penyebab utama syok kardiogenik, yaitu infark miokard akut dengan angka mortalitas mencapai 50%. Inotropik dan vasopresor telah menjadi landasan untuk stabilisasi gangguan hemodinamik dan curah jantung pada syok kardiogenik. Beberapa penelitian dan rekomendasi terbaru mengajukan dobutamin sebagai agen inotropik dan norepinefrin dibandingkan dopamin sebagai vasopressor lini pertama untuk tatalaksana syok kardiogenik.
Cardiogenic shock is a life-threatening medical emergency because of tissue hypoperfusion due to reduced cardiac output. The main cause of cardiogenic shock is acute myocardial infarction with mortality rate reaching 50%. Inotropics and vasopressors have been the basis for stabilization of hemodynamic instability and cardiac output in cardiogenic shock. Recent studies and recommendations recommend that dobutamine and norepinephrine is preferred over dopamine as a first-line vasopressor for patients with cardiogenic shock.
Unduhan
Referensi
Rathod KS, Koganti S, Iqbal MB, Jain AK, Kalra SS, Astroulakis Z, et al. Contemporary trends in cardiogenic shock: Incidence, intra-aortic balloon pump utilisation and outcomes from the London Heart Attack Group. Eur Heart J Acute Cardiovasc Care. 2018;7(1):16-27.
Jeger RV, Radovanovic D, Hunziker PR, Pfisterer ME, Stauffer JC, Erne P, et al. Ten-year trends in the incidence and treatment of cardiogenic shock. Ann Intern Med. 2008;149(9):618-26.
van Diepen S, Katz JN, Albert NM, Henry TD, Jacobs AK, Kapur NK, et al. Contemporary management of cardiogenic shock: A scientific statement from the American Heart Association. Circulation. 2017;136(16):232-68.
Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. 2012;367(14):1287-96.
Mebazaa A, Combes A, van Diepen S, Hollinger A, Katz JN, Landoni G, et al. Management of cardiogenic shock complicating myocardial infarction. Intensive Care Med. 2018;44(6):760-73.
Squara P, Hollenberg S, Payen D. Reconsidering vasopressors for cardiogenic shock: Everything should be made as simple as possible, but not simpler. Chest. 2019;156(2):392-401.
Reynolds HR, Hochman JS. Cardiogenic shock: Current concepts and improving outcomes. Circulation. 2008;117(5):686-97.
Thiele H, Ohman EM, de Waha-Thiele S, Zeymer U, Desch S. Management of cardiogenic shock complicating myocardial infarction: An update 2019. Eur Heart J. 2019;40(32):2671-83.
Thiele H, Ohman EM, Desch S, Eitel I, de Waha S. Management of cardiogenic shock. Eur Heart J. 2015;36(20):1223-30.
Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med. 1999;341(9):625-34.
Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Rev Esp Cardiol (Engl Ed). 2017;70(12):1082.
Kushner FG, Hand M, Smith SC, Jr., King SB, 3rd, Anderson JL, Antman EM, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2009;54(23):2205-41.
Stretch R, Sauer CM, Yuh DD and Bonde P. National trends in the utilization of short-term mechanical circulatory support: incidence, outcomes, and cost analysis. J Am Coll Cardiol. 2014;64:1407-15.
Thiele H, Zeymer U, Thelemann N, Neumann FJ, Hausleiter J, Abdel-Wahab M, et al. Intraaortic balloon pump in cardiogenic shock complicating acute myocardial infarction: Long-term 6-year outcome of the randomized IABP-SHOCK II trial. Circulation. 2018;139:395–403.
Ouweneel DM, Eriksen E, Sjauw KD, van Dongen IM, Hirsch A, Packer EJ, et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. J Am Coll Cardiol. 2017;69(3):278-87.
Thiele H, Jobs A, Ouweneel DM, Henriques JPS, Seyfarth M, Desch S, et al. Percutaneous short-term active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta-analysis of randomized trials. Eur Heart J. 2017;38(47):3523-31.
VanValkinburgh D, McGuigan JJ. Inotropes and vasopressors. StatPearls. Treasure Island (FL) 2019.
Amado J, Gago P, Santos W, Mimoso J, de Jesus I. Cardiogenic shock: Inotropes and vasopressors. Rev Port Cardiol. 2016;35(12):681-95.
Overgaard CB, Dzavik V. Inotropes and vasopressors: Review of physiology and clinical use in cardiovascular disease. Circulation. 2008;118(10):1047-56.
Jentzer JC, Coons JC, Link CB, Schmidhofer M. Pharmacotherapy update on the use of vasopressors and inotropes in the intensive care unit. J Cardiovasc Pharmacol Ther. 2015;20(3):249-60.
Zimmerman J, Lee JP, Cahalan M. Vasopressors and inotropes [Internet]. 2019:520-34. Available from: https://www.sciencedirect.com/science/article/pii/B9780323481106000259
Francis GS, Bartos JA, Adatya S. Inotropes. J Am Coll Cardiol. 2014;63(20):2069-78.
Mayhew DJ, Palmer K. Inotropes. Anaesth Intensive Care Med Anaesthesia and Intensive Care Medicine. 2015;16(10):508-12.
Friedrich JO, Adhikari N, Herridge MS, Beyene J. Meta-analysis: Low-dose dopamine increases urine output but does not prevent renal dysfunction or death. ACP journal club. 2005;143(2):42.
Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J. Low-dose dopamine in patients with early renal dysfunction: A placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet. 2000;356(9248):2139-43.
Cuffe MS, Califf RM, Adams KF, Jr., Benza R, Bourge R, Colucci WS, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: A randomized controlled trial. JAMA. 2002;287(12):1541-7.
Packer M, Colucci W, Fisher L, Massie BM, Teerlink JR, Young J, et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail. 2013;1(2):103-11.
Husebye T, Eritsland J, Muller C, Sandvik L, Arnesen H, Seljeflot I, et al. Levosimendan in acute heart failure following primary percutaneous coronary interventiontreated acute ST-elevation myocardial infarction. Results from the LEAF trial: A randomized, placebo-controlled study. Eur J Heart Fail. 2013;15(5):565-72.
Bangash MN, Kong M-L, Pearse RM. Use of inotropes and vasopressor agents in critically ill patients. British Journal of Pharmacology. 2012;165(7):2015-33.
Holmes CL, Landry DW, Granton JT. Science review: Vasopressin and the cardiovascular system part 1--receptor physiology. Critical care (London, England). 2003;7(6):427-34.
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-200.
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr., Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):1810-52.
De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med.2010;362(9):779-89.
Sakr Y, Reinhart K, Vincent JL, Sprung CL, Moreno R, Ranieri VM, et al. Does dopamine administration in shock influence outcome? Results of the sepsis occurrence in acutely ill patients (SOAP) Study. Critical care medicine. 2006;34(3):589-97.
Levy B, Perez P, Perny J, Thivilier C, Gerard A. Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Crit Care Med. 2011;39(3):450-5.
Albanese J, Leone M, Garnier F, Bourgoin A, Antonini F, Martin C. Renal effects of norepinephrine in septic and nonseptic patients. Chest. 2004;126(2):534-9.
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2021 Cermin Dunia Kedokteran
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.
